What are the concept stocks of antigen testing in COVID-19?

The concept stocks of antigen testing industry in COVID-19 are Wanfu Bio, Hong Qian Pharmaceutical and Lihai Bio.

Li Hai Bio: In the first quarter of 2002 1.0 1 billion yuan, the company's total revenue and earnings per share were 0.02 1 yuan.

COVID-19 antigen test kit (colloidal gold method), a wholly-owned subsidiary of Lihai Bio-technology, obtained the qualification of EU CE access. According to the intraday news on June 30th, the share price of Lihai Bio dropped by 1.06% in five days, and increased by 16.27% this year. The latest report was 14.89 yuan, down by 1. 13%, and the price-earnings ratio was/kloc-.

Hong Qian Pharmaceutical: In the first quarter of 200210, the company's total revenue was 39 1 100 million, with a gross profit margin of 44.56% and earnings per share of 0.0400 yuan.

Hong Qian Pharmaceutical said on the interactive platform that Jinghong Ke Sheng, a holding subsidiary of the company, specializes in the research and development and production of molecular diagnostic reagents. At present, the self-developed COVID-19 antigen detection reagent has been listed in the white list of export epidemic prevention materials of the Ministry of Commerce and started to be sold. In addition, COVID-19 nucleic acid detection kit and fusion antibody detection reagent for judging the effectiveness of COVID-19 vaccination are also under development.

20021June 30th morning news, the latest offer of Hong Qian Pharmaceutical was 4.08 yuan, up 0.49%, and its share price fell 0.49% within 3 days. Since the beginning of this year, the growth rate has dropped by -4.68%, and the P/E ratio is -37.

Wanfu Bio: In the first quarter of 200210, the company's total revenue was 697 million yuan, and earnings per share was 0.4600 yuan.

Wanfu Bio: It is estimated that the net profit in 2020 will be 580-660 million yuan, a year-on-year increase of 50%-70%. Driven by the continuous demand for COVID-19 detection products in domestic and foreign markets, the sales of COVID-19 antibody detection reagents and COVID-19 antigen detection reagents of the company increased rapidly, which brought strong impetus to the company's performance growth in 2020.

Wanfu Bio (300482) rose 1.22% to 63.68 yuan, with a turnover of 28.7436 million yuan, with a turnover rate of 0. 14% and an amplitude of 0.890%.

The data selected in this paper are for reference only, and cannot fully and accurately reflect the future of any enterprise, and do not constitute investment advice. So you have to act accordingly, at your own risk.